drugset / Trial / NCT02462538
Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL
NaSingle-groupOpen-labelTreatment
Summary
This is an open label pilot study of combining BV in a licensed indication with imatinib in patients with ALCL. It is intended as a "window of opportunity" trial in which the study drugs will be given as an initial substitute for conventional chemotherapy with the intention to achieve a remission enabling the patients to proceed to autologous or allogeneic stem cell transplantation, if eligible.
Timeline
- Start
- 2015-11-03
- Primary completion
- 2021-11-03
- Completion
- 2021-11-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brentuximab Vedotin | Monoclonal antibody | 1.8 mg/kg | Intravenous |
| Subject | Imatinib | Small molecule | 200 mg | Oral |